Drug General Information (ID: DDIJQUSDVX)
Drug Name			Cyclosporine		Drug Info		Bendroflumethiazide		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiviral Agents				Antihypertensive Agents
Structure

Mechanism of Cyclosporine-Bendroflumethiazide Interaction (Severity Level: Moderate)
Increased risk of hypermagnesemia Click to Show/Hide Mechanism Graph
Drug Name		Cyclosporine				Bendroflumethiazide
Mechanism 1		Hypermagnesemia				Hypermagnesemia
Key Mechanism Factor 1
		Factor Name		Hypermagnesemia
		Factor Description		Hypomagnesemia is a condition that occurs when you have too much magnesium in your body. Symptoms of hypomagnesemia include: nausea, vomiting, neurological damage, abnormally low blood pressure (hypotension), flushing, and headaches.
Mechanism Description		Increased risk of hypermagnesemia by the combination of Cyclosporine and Bendroflumethiazide
Increased risk of nephrotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Cyclosporine				Bendroflumethiazide
Mechanism 2		Nephrotoxicity				Nephrotoxicity
Key Mechanism Factor 2
		Factor Name		Nephrotoxicity
		Factor Description		The combination of drugs that can induce nephrotoxicity may increase the risk of kidney injury. When kidney injury occurs, the inability to remove excess urine and waste from the body can lead to high levels of urea nitrogen, creatinine, and electrolytes (such as potassium and magnesium) in the blood.
Mechanism Description		Increased risk of nephrotoxicity by the combination of Cyclosporine and Bendroflumethiazide

Recommended Action
Management		Monitoring of renal function, serum electrolytes, uric acid levels, and cyclosporine blood concentrations is advisable during concomitant use. Some authorities advise against concomitant use of these medicines.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Multum Information Services, Inc. Expert Review Panel.